榄香烯注射液辅助VAD化疗治疗多发性骨髓瘤

Clinical Analysis of Elemene Injection Adjuvant VAD Chemotherapy Treatment Multiple Myeloma

目的:研究榄香烯注射液辅助VAD化疗的临床疗效及安全性。方法:选择在我院就诊的多发性骨髓瘤患者作为研究对象,随机分为给予榄香烯注射液辅助VAD化疗的观察组和VAD化疗的对照组,VCD化疗采用静脉注射长春新碱(0.4 mg)、阿霉素(9 mg)、口服地塞米松(40 mg),榄香烯注射液(0.4 g)静脉滴注。观察缓解情况、免疫功能及不良反应。结果:观察组的完全缓解率(38.46%)、部分缓解率(46.25%)以及CD3+(68.38±9.03)%,CD4+(47.18±8.49)%,CD4+/CD8+(2.17±0.42),自然杀伤细胞(NK)(9.31±1.34)%,肿瘤坏死因子-α(TNF-α)(1.53±0.21)ng·L-1,提高稳定率(92.31%)等高于对照组;CD8+(21.75±5.68)%以及头痛头晕(23.08%)、消化道症状(7.69%)、肾功能损害(7.69%)、肝功能损害(7.69%)、心功能损害(15.38%)、骨髓抑制(7.69%)均明显少于对照组。结论:榄香烯注射液辅助VAD化疗能够提高化疗缓解率、改善免疫功能、减少不良反应,具有积极的临床价值。

Objective： To study the clinical efficacy and safety of elemene injection adjuvant VAD chemotherapy. Method： Multiple myeloma patients were collected and randomLy divided into observation group given elemene injection adjuvant VAD chemotherapy and Vcontrol group given VAD chemotherapy. VCD chemotherapy using intravenous vincristine （0.4 mg）,adriamycin （9 mg）,oral dexamethasone （40 mg）,Elemene injection intravenous drip （0.4 g）. Then remission,immune function and adverse reaction were observed. Result： Tcomplete remission rate （38.46% ）,partial remission rate （46.25% ）and CD3＋（68.38±9.03）%,CD4＋（47.18±8.49）%,CD4＋/CD8＋（2.17±0.42）,natural killer cells（NK）（9.31±1.34）%,tumor necrosis factor-α（TNF-α）（1.530.21）ng L-1 levels,Improve the stability factor （92.31% ） of observation group were higher than control group;CD8＋（21.75±5.68）%,Headache dizziness （23.08% ）,gastrointestinal symptoms （7.69% ）,renal impairment （7.69% ）,liver function damage （7.69% ）,heart function damage （15.38% ）,bone marrow suppression （7.69% ） were significantly less thancontrol group. Conclusion： Elemene injection adjuvant VAD chemotherapy has positive clinical value for it can improve remission and immune function,reduce adverse reaction.